Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM
Lancet Diabetes Endocrinol (2024) · n=386
Survodutide 4.8 mg produced 14.9% mean body-weight reduction at 46 weeks versus 2.8% on placebo — the first Phase 2 obesity readout for a glucagon / GLP-1 dual agonist competitive with tirzepatide-class magnitudes.
This is the Phase 2 dose-finding trial that established survodutide — Boehringer Ingelheim's glucagon and GLP-1 receptor dual agonist (BI 456906) — as a competitive candidate in the next-generation obesity pharmacotherapy class. Le Roux and colleagues at 43 centers across 12 countries randomized 387 adults with obesity (BMI ≥27) without diabetes in a 1:1:1:1:1 ratio to once-weekly subcutaneous survodutide at four target doses (0.6, 2.4, 3.6, 4.8 mg) or placebo. The trial used a 20-week dose-escalation phase followed by 26 weeks of maintenance, for 46 weeks total. The primary endpoint was percent change in body weight from baseline to week 46.
Body-weight reductions were dose-dependent and substantial: -6.2% on 0.6 mg, -12.5% on 2.4 mg, -13.2% on 3.6 mg, -14.9% on 4.8 mg, versus -2.8% on placebo. Cardiometabolic risk factors (systolic blood pressure, lipids, glycated hemoglobin) improved across active doses. Adverse events occurred in 91% of survodutide recipients versus 75% of placebo recipients, predominantly gastrointestinal (nausea, vomiting, diarrhea) and concentrated during dose escalation. Discontinuations for adverse events were higher in the higher-dose arms. The trial was sponsored by Boehringer Ingelheim; three authors were company employees.
The result situated survodutide within the same magnitude range as the SURMOUNT-1 tirzepatide readout at the head-to-head dose comparison, though direct comparison is constrained by different trial durations, populations, and titration schedules. Survodutide's mechanism differs in a structurally important way: the addition of glucagon receptor agonism is hypothesized to increase energy expenditure (rather than acting primarily through appetite suppression and delayed gastric emptying as the GLP-1-only and GIP/GLP-1 classes do). Whether that mechanistic difference translates into a different body-composition or long-term-tolerability profile is the question the Phase 3 SYNCHRONIZE program is designed to answer.
The 46-week duration is appropriate for a dose-finding Phase 2 but short relative to the chronic-therapy positioning the obesity field has converged on; weight-loss plateau and post-treatment regain dynamics for survodutide are not addressed in this readout. Comparisons of headline weight-loss percentages across trials are notoriously misleading — placebo arms behave differently across populations and run-in protocols, titration schedules differ, and trial duration affects asymptote. The 14.9% versus 22.5% comparison between survodutide 4.8 mg here and tirzepatide 15 mg in SURMOUNT-1 should be read as "in the same league" rather than "ranked."
The 91% adverse-event rate in survodutide recipients — even with mild-moderate dominance — represents the practical tolerability ceiling for the molecule and is higher than the GI burden reported in the comparable SURMOUNT-1 arms. Whether faster glucagon receptor engagement contributes to the GI signal, or whether slower titration would mitigate it without sacrificing efficacy, is partially addressed in the head-to-head T2D trial against semaglutide but not resolved.
Industry sponsorship by Boehringer Ingelheim is disclosed; design, conduct, and analysis appear consistent with regulatory expectations. The trial population was predominantly European and White; generalizability to other populations and to patients with T2D, MASH, or established cardiovascular disease is being addressed in companion programs (T2D head-to-head, MASH Phase 2). Phase 3 readouts had not yet published as of mid-2026.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.